Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jerome Benedict Durso
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Beta
- 0.18
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.31
Financials
Revenue
$0.00-100.0%Net Income
$-22.82M-120.9%EBITDA
$-26.20MFree Cash Flow
$-24.25M-121.8%EPS (diluted)
$-0.12Shares Outstanding (diluted)
185.44M+80391.9%Operating Expenses
$26.23MCash & Debt
$326.32MReturn of Capital
$0.00Revenue by Segment (annual)
$3.70MDividend per Share
$873.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $41.0K | $-88.09M | $-1.00 |
| 2024 | $20.0K | $-95.06M | $-1.34 |
| 2023 | $426.0K | $-88.45M | $-1.66 |
| 2022 | $-68.0K | $-84.71M | $-1.81 |
| 2021 | $4.41M | $-97.09M | $-2.35 |
| 2020 | $8.19M | $-49.04M | $-1.91 |
| 2019 | $5.80M | $-20.52M | $-1.56 |
| 2018 | $10.33M | $-39.17M | $-13.98 |
| 2017 | $41.5K | $-46.43M | $-108.77 |
| 2016 | $5.23M | $193.85M | $-49.80 |
| 2015 | $10.64M | $-3.44M | $-16.13 |
| 2014 | $10.19M | $-9.96M | $-51.91 |
| 2013 | $17.91M | $-11.72M | $-69.40 |
| 2012 | $25.18M | $-4.92M | $-30.55 |
Valuation
ALThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-55.32%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·5d ago·Positive
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Altimmune to Participate in Stifel Cardiometabolic Forum GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
View source ↗ - Newszacks.com·24d ago·Neutral
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the Alpha Liquid Terminal ("ALTx"), today announced the relaunch of its platform as the ALT/X Compute Terminal , refocusing the product on pricing, power and capacity data for the global AI compute market.
View source ↗ - Newszacks.com·47d ago·Negative
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
View source ↗ - Newszacks.com·47d ago·Positive
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
View source ↗ - Newszacks.com·53d ago·Negative
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Altimmune Q2 Earnings Call Highlights Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Altimmune Announces Second Quarter 2026 Financial Results and Business Update Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.14 per share
Typical surprise +15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.12 vs $-0.14beat
- Wed, May 13$-0.18 vs $-0.25beat
- Thu, Mar 5$-0.27 vs $-0.25miss
- Thu, Nov 6$-0.21 vs $-0.29beat
- Tue, Aug 12$-0.27 vs $-0.32beat
- Tue, May 13$-0.26 vs $-0.35beat
Estimates and results for ALT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALT officers and directors.
- Bought
- $428k
- Sold
- —
13 trades
0 trades
- Durso Jerome Benedictbought
- Gill Johnbought
- Weaver Gregory Lbought
- Durso Jerome Benedictbought
- Weaver Gregory Lbought
- Durso Jerome Benedictbought
- Pisano Waynebought
- Sohn Catherine A.bought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.